Table 4.
25(OH)D ng/mL |
NAM/NIH | ES | NOS | SACN | AGS * | ESE |
---|---|---|---|---|---|---|
<10 | deficiency | deficiency | deficiency | deficiency | deficiency | deficiency |
10–20 | inadequacy risk | deficiency | inadequacy risk | sufficient | deficiency | deficiency |
20–30 | sufficiency | insufficiency | sufficiency | sufficient | deficiency risk | insufficiency |
30–50 | sufficiency | desirable concentration | sufficiency | sufficient | minimal acceptable concentration | sufficiency |
50–100 | possible excess adverse events | desirable concentration | possible onset of toxicity | |||
100–150 | possible excess adverse events | possible onset of toxicity | ||||
>150 | toxicity |
NAM: National Academy of Medicine (former Institute of Medicine, IOM), USA; NIH: National Institute of Health, USA; ES: Endocrine Society, USA; NOS: National Osteoporosis Society, UK; SACN: Scientific Advisory Committee on Nutrition, UK; American Geriatrics Society, USA; ESE: European Society of Endocrinology. * Values applicable to old age.